阿托伐他汀联合曲美他嗪对冠心病患者氧化应激、血液流变学及NT-proBNP、hs-CRP的影响

摘要

目的:探讨阿托伐他汀联合曲美他嗪对冠心病患者氧化应激、血液流变学及NT-proBNP、hs-CRP的影响.方法:选择84例于我院进行治疗的冠心病患者,随机分为观察组和对照组各42例.两组均接受冠心病的常规治疗,对照组加用阿托伐他汀治疗,观察组加用阿托伐他汀联合曲美他嗪治疗,两组均持续用药一个月.比较两组氧化应激指标:超氧化物歧化酶(SOD)、丙二醛(MDA),血液流变学指标:血沉、全血低切黏度、全血高切黏度、血浆粘度、纤维蛋白原(Fib)以及血浆N端脑钠肽前体(NT-proBNP)、高敏C反应蛋白(hs-CRP)指标的水平.结果:治疗前,观察组和对照组的氧化应激、血液流变学、NT-proBNP、hs-CRP指标之间比较差异无统计学意义(P>0.05).与治疗前相比,治疗后观察组与对照组的SOD均显著升高,MDA均显著降低,差异均有统计学意义(P<0.05);治疗后,观察组的SOD高于对照组,观察组的MDA低于对照组,差异均有显著性(P<0.05).与治疗前相比,治疗后观察组与对照组的血沉、全血黏度、血浆粘度和Fib等血液流变学指标均显著降低(P<0.05);治疗后,观察组的血沉、全血黏度、血浆粘度和Fib指标均显著低于对照组,各组差异均具有显著性(P<0.05).相比于治疗前,治疗后两组NT-proBNP、hs-CRP水平均明显减少(P<0.05);治疗后观察组NT-proB-NP、hs-CRP均明显低于对照组,差异有统计学意义(P<0.05).结论:阿托伐他汀联合曲美他嗪治疗冠心病可明显降低氧化应激损伤、炎症反应及恢复正常的血液流变学水平,改善患者临床症状,值得推广.%Objective:To explore the effect of Atorvastatin Combined with trimetazidine on oxidative stress,hemorheo-logy and NT-proBNP and hs-CRP in patients with coronary heart disease.Method:84 patients with coronary heart disease trea-ted in our hospital from February 2015 to February 2017 were randomly divided into the observation group and the control group,each with 42 cases.The two groups received routine treatment of coronary heart disease,while the control group was treated with atorvastatin and the observation group was treated with Atorvastatin Combined with trimetazidine.The two groups were treated continuously for one month.The levels of oxidative stress indexes (SOD,MDA),blood rheology indexes (ESR, whole blood viscosity at both high and low shear rates,plasma viscosity,Fib)and serum NT-proBNP、hs-CRP index in two groups were compared analytically.Results:Before treatment,there was no significant difference between the observation group and the control group in terms of oxidative stress,blood rheology and NT-proBNP and hs-CRP index (P <0.05).Com-pared with treatment before,the level of SOD in observation group and the control group was significantly increased and MDA significantly decreased (P <0.05).While the level of SOD in observation group was significantly higher than the control group, and MDA level was significantly lower than the control group after treatment (P <0.05).Compared with treatment before,the levels of hemorheology indexes included ESR,whole blood viscosity,plasma viscosity and Fib in he observation group and con-trol group were significantly decreased (P <0.05).After treatment,the levels of ESR,whole blood viscosity at both high and low shear rates,plasma viscosity and Fib in the observation group were significantly lower than the control group (P <0.05). Compared with treatment before,the levels of NT-proBNP and hs-CRP in the observation group and control group were signif-icantly decreased (P <0.05).After treatment,the levels of NT-proBNP and hs-CRP in the observation group were significantly lower than the control group (P <0.05 ).Conclusion:Atorvastatin Combined with trimetazidine treatment of coronary heart disease can significantly reduce oxidative stress ,restore normal blood rheology,and improve levels of NT-proBNP and hs-CRP. This treatment is worthy of clinical promotion.